Corporate Social Responsibility Report

The report describes PharmaMar Group's 2015 transition from Zeltia following the reverse merger, while retaining a portfolio spanning biopharmaceuticals and consumer chemicals. It reports 700 employees at year-end and highlights more than 63.5 million euro in PharmaMar R&D spending, up 21% year on year. Environmentally, PharmaMar and Xylazel were certified to ISO 14001, and the Group reports no material environmental accidents, fines or lawsuits in 2015.